Evidence map›Paper›PMID 40016594›Full record

ArticleCommunications medicine2025

Urinary metabolite model to predict the dying process in lung cancer patients.

Séamus Coyle, Elinor Chapman, David M Hughes, James Baker, Rachael Slater, Andrew S Davison, Brendan P Norman, Ivayla Roberts, Amara C Nwosu, James A Gallagher and 7 more

Abstract read
In one paragraph

Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Séamus CoyleLiverpool Head and Neck Cancer Centre, University of Liverpool, Liverpool, UK. s.coyle@liverpool.ac.uk.ORCID http://orcid.org/0000-0002-4761-9703
Elinor ChapmanInstitute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.ORCID http://orcid.org/0000-0002-4398-1705
David M HughesDepartment of Health Data Science, University of Liverpool, Liverpool, UK.ORCID http://orcid.org/0000-0002-1287-9994
James BakerInstitute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.ORCID http://orcid.org/0000-0002-6562-1081
Rachael SlaterInstitute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.ORCID http://orcid.org/0000-0001-9765-6978
Andrew S DavisonDepartment of Clinical Biochemistry and Metabolic Medicine, Liverpool Clinical Laboratories, Liverpool University Hospitals Foundation Trust, Liverpool, UK.ORCID http://orcid.org/0000-0001-5501-4475
Brendan P NormanInstitute of Life Course & Medical Sciences, University of Liverpool, Liverpool, UK.ORCID http://orcid.org/0000-0001-9293-4852
Ivayla RobertsInstitute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.ORCID http://orcid.org/0000-0003-3525-9787
Amara C NwosuLancaster Medical School, Lancaster University, Lancaster, UK.ORCID http://orcid.org/0000-0003-0014-3741
James A GallagherInstitute of Life Course & Medical Sciences, University of Liverpool, Liverpool, UK.
Lakshminarayan R RanganathDepartment of Clinical Biochemistry and Metabolic Medicine, Liverpool Clinical Laboratories, Liverpool University Hospitals Foundation Trust, Liverpool, UK.ORCID http://orcid.org/0000-0002-4205-2269
Mark T BoydLiverpool Head and Neck Cancer Centre, University of Liverpool, Liverpool, UK.ORCID http://orcid.org/0000-0002-2336-2106
Catriona R MaylandPalliative Care Unit, Institute of Life Course & Medical Sciences, University of Liverpool, Liverpool, UK.ORCID http://orcid.org/0000-0002-1440-9953
Douglas B KellCentre for Metabolomics Research (CMR), Department of Biochemistry, Cell and Systems Biology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.ORCID http://orcid.org/0000-0001-5838-7963
Stephen MasonPalliative Care Unit, Institute of Life Course & Medical Sciences, University of Liverpool, Liverpool, UK.ORCID http://orcid.org/0000-0002-4020-6869
John EllershawPalliative Care Unit, Institute of Life Course & Medical Sciences, University of Liverpool, Liverpool, UK.ORCID http://orcid.org/0000-0001-9789-3180
Chris ProbertInstitute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.ORCID http://orcid.org/0000-0003-4550-0239

Funding

North West Cancer Research Fund (NWCR) SI2018.11Novo Nordisk Fonden (Novo Nordisk Foundation) NNF20CC0035580Wellcome Trust
6 · The paper itself

Abstract

backgroundAccurately recognizing that a person may be dying is central to improving their experience of care at the end-of-life. However, predicting dying is frequently inaccurate and often occurs only hours or a few days before death.

methodsWe performed urinary metabolomics analysis on patients with lung cancer to create a metabolite model to predict dying over the last 30 days of life.

resultsHere we show a model, using only 7 metabolites, has excellent accuracy in the Training cohort n = 112 (AUC = 0·85, 0·85, 0·88 and 0·86 on days 5, 10, 20 and 30) and Validation cohort n = 49 (AUC = 0·86, 0·83, 0·90, 0·86 on days 5, 10, 20 and 30). These results are more accurate than existing validated prognostic tools, and uniquely give accurate predictions over a range of time points in the last 30 days of life. Additionally, we present changes in 125 metabolites during the final four weeks of life, with the majority exhibiting statistically significant changes within the last week before death.

conclusionsThese metabolites identified offer insights into previously undocumented pathways involved in or affected by the dying process. They not only imply cancer's influence on the body but also illustrate the dying process. Given the similar dying trajectory observed in individuals with cancer, our findings likely apply to other cancer types. Prognostic tests, based on the metabolites we identified, could aid clinicians in the early recognition of people who may be dying and thereby influence clinical practice and improve the care of dying patients.

Identifiers

PMID40016594
PMCPMC11868640

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.